Nancy Bartlett

Research output

Research output per year 1989 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2023

• 225 Article
• 34 Review article
• 20 Letter
• 8 Comment/debate
• 8 More
  • 4 Chapter
  • 4 Editorial

Research output per year

Research output per year

Search results

• 2023

  A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

  Merryman, R. W., Redd, R. A., Freedman, A. S., Ahn, I. E., Brown, J. R., Crombie, J. L., Davids, M. S., Fisher, D. C., Jacobsen, E. D., Kim, A. I., LaCasce, A. S., Ng, S., Odejide, O. O., Parry, E. M., Isufi, I., Kline, J., Cohen, J. B., Mehta-Shah, N., Bartlett, N. L., Mei, M., & 5 othersKuntz, T. M., Wolff, J., Rodig, S. J., Armand, P. & Jacobson, C. A., 2023, (Accepted/In press) In: Annals of Hematology.

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • utomilumab 92%
  • Rituximab 88%
  • Immunotherapy 71%
  • avelumab 47%

• Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies

  Patel, D. A., Wan, F., Trinkaus, K., Guy, D. G., Edwin, N., Watkins, M., Bartlett, N. L., Cashen, A., Fehniger, T. A., Ghobadi, A., Shah, N. M. & Kahl, B. S., Jul 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 7, p. 552-560 9 p.

  Research output: Contribution to journal › Article › peer-review

  • acalabrutinib 100%
  • Bendamustine Hydrochloride 79%
  • Mantle-Cell Lymphoma 67%
  • Cytarabine 59%
  • Rituximab 56%

• Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

  Russler-Germain, D. A., Cliff, E. R. S. & Bartlett, N. L., 2023, (Accepted/In press) In: Blood.

  Research output: Contribution to journal › Article › peer-review

  • polatuzumab vedotin 100%
  • Lymphoma, Large B-Cell, Diffuse 58%
  • B-Cell Lymphoma 53%
  • Cell Communication 48%
  • B-Lymphocytes 39%

• Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

  Roddie, C., Lekakis, L. J., Marzolini, M. A. V., Ramakrishnan, A., Zhang, Y., Hu, Y., Peddareddigari, V. G. R., Khokhar, N., Chen, R., Basilico, S., Raymond, M., Vargas, F. A., Duffy, K., Brugger, W., O'Reilly, M. A., Wood, L., Linch, D. C., Peggs, K. S., Bachier, C., Budde, E. L., & 7 othersLee Batlevi, C., Bartlett, N., Irvine, D., Tholouli, E., Osborne, W., Ardeshna, K. M. & Pule, M. A., May 18 2023, In: Blood. 141, 20, p. 2470-2482 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Refractory 76%
  • B-Cell Lymphoma 76%
  • Antigen 62%
  • T-Lymphocytes 45%
  14 Scopus citations

• FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV_max as a predictive biomarker in frontline treatment of mantle cell lymphoma

  Russler-Germain, D. A., Calhoun, B. R., Wu, N., Watkins, M. P., Siegel, B. A., Bartlett, N. L. & Mhlanga, J. C., 2023, In: Leukemia and Lymphoma. 64, 11, p. 1870-1874 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

  Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P., Flinn, I. W., Farooq, U., Goy, A. H., McSweeney, P. A., Munoz, J., Siddiqi, T., Chavez, J. C., & 10 othersHerrera, A. F., Bartlett, N. L., Bot, A. A., Shen, R. R., Dong, J., Singh, K., Miao, H., Kim, J. J., Zheng, Y. & Locke, F. L., May 11 2023, In: Blood. 141, 19, p. 2307-2315 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • Refractory 53%
  • B-Cell Lymphoma 53%
  • Safety 43%
  • Antigen 43%
  29 Scopus citations

• Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

  Thomas, N., Dreval, K., Gerhard, D. S., Hilton, L. K., Abramson, J. S., Ambinder, R. F., Barta, S., Bartlett, N. L., Bethony, J., Bhatia, K., Bowen, J., Bryan, A. C., Cesarman, E., Casper, C., Chadburn, A., Cruz, M., Dittmer, D. P., Dyer, M. A., Farinha, P., Gastier-Foster, J. M., & 48 othersGerrie, A. S., Grande, B. M., Greiner, T., Griner, N. B., Gross, T. G., Harris, N. L., Irvin, J. D., Jaffe, E. S., Henry, D., Huppi, R., Leal, F. E., Lee, M. S., Martin, J. P., Martin, M. R., Mbulaiteye, S. M., Mitsuyasu, R., Morris, V., Mullighan, C. G., Mungall, A. J., Mungall, K., Mutyaba, I., Nokta, M., Namirembe, C., Noy, A., Ogwang, M. D., Omoding, A., Orem, J., Ott, G., Petrello, H., Pittaluga, S., Phelan, J. D., Ramos, J. C., Ratner, L., Reynolds, S. J., Rubinstein, P. G., Sissolak, G., Slack, G., Soudi, S., Swerdlow, S. H., Traverse-Glehen, A., Wilson, W. H., Wong, J., Yarchoan, R., ZenKlusen, J. C., Marra, M. A., Staudt, L. M., Scott, D. W. & Morin, R. D., Feb 23 2023, In: Blood. 141, 8, p. 904-916 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Burkitt Lymphoma 100%
  • Lethal 99%
  • Mutation 70%
  • Pediatrics 53%
  • Lymphoma, Large B-Cell, Diffuse 11%
  12 Scopus citations

• Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia

  Johnson, P. C., Woyach, J. A., Ulrich, A., Marcotte, V., Nipp, R. D., Lage, D. E., Nelson, A. M., Newcomb, R. A., Rice, J., Lavoie, M. W., Ritchie, C. S., Bartlett, N., Stephens, D. M., Ding, W., Owen, C., Stone, R., Ruppert, A. S., Mandrekar, S. J., Byrd, J. C., El-Jawahri, A., & 2 othersLe-Rademacher, J. & Rosko, A., Jul 2023, In: Journal of Geriatric Oncology. 14, 6, 101538.

  Research output: Contribution to journal › Article › peer-review

  • Geriatric Assessment 100%
  • B-Cell Chronic Lymphocytic Leukemia 81%
  • Geriatrics 72%
  • Health Care Outcome Assessment 50%
  • PCI 32765 28%
  2 Scopus citations

• Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

  Epperla, N., Zhao, Q., Karmali, R., Torka, P., Shea, L., Oh, T. S., Anampa-Guzmán, A., Reves, H., Tavakkoli, M., Greenwell, I. B., Hansinger, E., Umyarova, E., Annunzio, K., Sawalha, Y., Christian, B., Thomas, C., Barta, S. K., Geethakumari, P. R., Bartlett, N. L., Grover, N. S., & 1 othersOlszewski, A. J., Sep 12 2023, In: Blood Advances. 7, 17, p. 5038-5046 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Paraproteins 100%
  • Multicenter Studies 61%
  • Lymphoma 58%
  • Cohort Studies 47%
  • Progression-Free Survival 29%
  1 Scopus citations

• Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

  Epperla, N., Switchenko, J., Bachanova, V., Gerson, J. N., Barta, S. K., Gordon, M. J., Danilov, A. V., Grover, N. S., Mathews, S., Burkart, M., Karmali, R., Sawalha, Y., Hill, B. T., Ghosh, N., Park, S. I., Bond, D. A., Hamadani, M., Fenske, T. S., Martin, P., Malecek, M. K., & 15 othersKahl, B. S., Flowers, C. R., Link, B. K., Kaplan, L. D., Inwards, D. J., Feldman, A. L., Hsi, E. D., Maddocks, K., Blum, K. A., Bartlett, N. L., Cerhan, J. R., Leonard, J. P., Habermann, T. M., Maurer, M. J. & Cohen, J. B., Jun 13 2023, In: Blood Advances. 7, 11, p. 2287-2296 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mantle-Cell Lymphoma 100%
  • Therapeutics 12%
  • Progression-Free Survival 10%
  • lactate dehydrogenase 2 9%
  • Molecular Epidemiology 6%
  2 Scopus citations

• Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

  Epperla, N., Welkie, R. L., Torka, P., Shouse, G., Karmali, R., Shea, L., Anampa-Guzmán, A., Oh, T. S., Reaves, H., Tavakkoli, M., Lindsey, K., Greenwell, I. B., Hansinger, E., Thomas, C., Chowdhury, S. M., Annunzio, K., Christian, B., Barta, S. K., Geethakumari, P. R., Bartlett, N. L., & 3 othersHerrera, A. F., Grover, N. S. & Olszewski, A. J., Dec 2023, In: Journal of Hematology and Oncology. 16, 1, 49.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Lymphoma 100%
  • Disease Progression 96%
  • Recurrence 68%
  • Survival 24%
  • Rituximab 23%
  3 Scopus citations

• Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis

  Torka, P., Pederson, L. D., Knopp, M. V., Poon, D., Zhang, J., Kahl, B. S., Higley, H. R., Kelloff, G., Friedberg, J. W., Schwartz, L. H., Wilson, W. H., Leonard, J. P., Bartlett, N. L., Schöder, H. & Ruppert, A. S., Apr 2023, In: Cancer medicine. 12, 7, p. 8211-8217 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Positron-Emission Tomography 82%
  • Progression-Free Survival 64%
  • Clinical Trials 57%
  • Survival 49%
  1 Scopus citations

• Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

  Bartlett, N. L., Assouline, S., Giri, P., Schuster, S. J., Cheah, C. Y., Matasar, M., Gregory, G. P., Yoon, D. H., Shadman, M., Fay, K., Yoon, S. S., Panizo, C., Flinn, I., Johnston, A., Bosch, F., Sehn, L. H., Wei, M. C., Yin, S., To, I., Li, C. C., & 4 othersHuang, H., Kwan, A., Penuel, E. & Budde, L. E., Sep 12 2023, In: Blood Advances. 7, 17, p. 4926-4935 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Cytokine Release Syndrome 40%
  • Confidence Intervals 22%
  • Chimeric Antigen Receptors 17%
  • Follicular Lymphoma 15%
  4 Scopus citations

• Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

  Russler-Germain, D. A., Krysiak, K., Ramirez, C., Mosior, M., Watkins, M. P., Gomez, F., Skidmore, Z. L., Trani, L., Gao, F., Geyer, S., Cashen, A. F., Mehta-Shah, N., Kahl, B. S., Bartlett, N. L., Alderuccio, J. P., Lossos, I. S., Ondrejka, S. L., Hsi, E. D., Martin, P., Leonard, J. P., & 3 othersGriffith, M., Griffith, O. L. & Fehniger, T. A., Sep 26 2023, In: Blood Advances. 7, 18, p. 5524-5539 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Follicular Lymphoma 100%
  • Mutation 45%
  • Progression-Free Survival 10%
  • Genes 7%
  • p53 Genes 4%

• Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

  Nastoupil, L. J. & Bartlett, N. L., Feb 1 2023, In: Journal of Clinical Oncology. 41, 4, p. 903-913 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Bispecific Antibodies 62%
  • Non-Hodgkin's Lymphoma 41%
  • Recurrence 25%
  • Therapeutics 14%
  3 Scopus citations

• Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

  Kuruvilla, J., Armand, P., Hamadani, M., Kline, J., Moskowitz, C. H., Avigan, D., Brody, J. D., Ribrag, V., Herrera, A. F., Morschhauser, F., Kanate, A., Zinzani, P. L., Bitran, J., Ghesquieres, H., Schuster, S. J., Farooqui, M., Marinello, P. & Bartlett, N. L., 2023, In: Leukemia and Lymphoma. 64, 1, p. 130-139 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Non-Hodgkin's Lymphoma 67%
  • Cell Transplantation 38%
  • Lenalidomide 23%
  • Safety 20%
  3 Scopus citations

• Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

  LaCasce, A. S., Dockter, T., Ruppert, A. S., Kostakoglu, L., Schöder, H., Hsi, E., Bogart, J., Cheson, B., Wagner-Johnston, N., Abramson, J., Blum, K., Leonard, J. P. & Bartlett, N. L., Feb 10 2023, In: Journal of Clinical Oncology. 41, 5, p. 1023-1034 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Positron-Emission Tomography 90%
  • Bleomycin 27%
  • Doxorubicin 22%
  • Progression-Free Survival 22%
  2 Scopus citations

• Postibrutinib relapse outcomes for patients with marginal zone lymphoma

  Epperla, N., Zhao, Q., Chowdhury, S. M., Shea, L., Moyo, T. K., Reddy, N., Sheets, J., Weiner, D. M., Geethakumari, P. R., Kandarpa, M., Bruno, X. J., Thomas, C., Churnetski, M. C., Hsu, A., Zurbriggen, L., Tan, X. W. C., Lindsey, K., Maakaron, J., Caimi, P. F., Torka, P., & 26 othersBello, C., Ayyappan, S., Oh, T. S., Karmali, R., Kim, S. H., Kress, A., Kothari, S., Sawalha, Y., Christian, B., David, K. A., Greenwell, I. B., Janakiram, M., Kenkre, V. P., Olszewski, A. J., Cohen, J. B., Palmisiano, N., Umyarova, E., Wilcox, R. A., Awan, F. T., Alderuccio, J. P., Barta, S. K., Grover, N. S., Ghosh, N., Bartlett, N. L., Herrera, A. F. & Shouse, G., Jan 10 2023, In: Blood Advances. 7, 1, p. 88-91 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

  Lakhotia, R., Dunleavy, K., Abramson, J. S., Link, B. K., Powell, B. L., Melani, C., Lucas, A. N., Steinberg, S. M., Friedberg, J. W., Kahl, B. S., Little, R. F., Bartlett, N. L., Noy, A., Wilson, W. H. & Roschewski, M., Sep 26 2023, In: Blood Advances. 7, 18, p. 5320-5324 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

  Rutherford, S. C., Yin, J., Pederson, L., Perez Burbano, G., Laplant, B., Shadman, M., Li, H., Leblanc, M. L., Kenkre, V. P., Hong, F., Blum, K. A., Dockter, T., Martin, P., Jung, S. H., Grant, B., Rosenbaum, C., Ujjani, C., Barr, P. M., Unger, J. M., Cheson, B. D., & 5 othersBartlett, N. L., Kahl, B., Friedberg, J. W., Mandrekar, S. J. & Leonard, J. P., Jan 10 2023, In: Journal of Clinical Oncology. 41, 2, p. 336-342 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • National Cancer Institute (U.S.) 94%
  • Bone Marrow 59%
  • Clinical Trials 52%
  • Biopsy 49%
  6 Scopus citations
• 2022

  Bispecific Antibodies in Lymphoma - Another Win for T Cells.

  Bartlett, N. L., Dec 15 2022, In: New England Journal of Medicine. 387, 24, p. 2285-2286 2 p.

  Research output: Contribution to journal › Editorial
  1 Scopus citations

• Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

  Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, A. M., Smith, S. M., Horwitz, S. M., Ansell, S. M. & Advani, R. H., May 1 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 5, p. e300-e309

  Research output: Contribution to journal › Article › peer-review

  • Extranodal NK-T-Cell Lymphoma 100%
  • North America 65%
  • Natural Killer T-Cells 45%
  • T-Cell Lymphoma 44%
  • Combined Modality Therapy 38%
  1 Scopus citations

• Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

  Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, A. M., Smith, S. M., Horwitz, S. M., Ansell, S. M. & Advani, R. H., Apr 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 4, p. e250-e260

  Research output: Contribution to journal › Article › peer-review

  • Extranodal NK-T-Cell Lymphoma 100%
  • North America 65%
  • Natural Killer T-Cells 40%
  • T-Cell Lymphoma 39%
  • Combined Modality Therapy 33%

• COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

  Mehta-Shah, N., Bartlett, N. L., Kahl, B., Watkins, M. P., Dubois, A., Schmelzle, G., Waqar, S., Ballman, C., Wan, F. & Farnsworth, C. W., 2022, In: Leukemia and Lymphoma. 63, 7, p. 1723-1727 5 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

  Carlo-Stella, C., Ansell, S., Zinzani, P. L., Radford, J., Maddocks, K., Pinto, A., Collins, G. P., Bachanova, V., Bartlett, N., Bence-Bruckler, I., Hamadani, M., Kline, J., Mayer, J., Savage, K. J., Advani, R., Calmi, P., Casasnovas, R. O., Feldman, T., Hess, B., Bastos-Oreiro, M., & 6 othersIyengar, S., Eisen, S., Negievich, Y., Wang, L., Wuerthner, J. & Herrera, A. F., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S347

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Safety 56%
  • Polyradiculopathy 35%
  • Exanthema 21%
  • pyrrolo(2,1-c)(1,4)benzodiazepine 20%

• HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

  Straus, D., Radford, J., Connors, J., Kim, W. S., Gallamini, A., Ramchandren, R., Friedberg, J., Advani, R., Hutchings, M., Evens, A., Smolewski, P., Savage, K., Bartlett, N., Eom, H. S., Abramson, J., Dong, C., Campana, F., Fenton, K., Puhlmann, M. & Ansell, S., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S350

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Hodgkin Disease 64%
  • Drug Therapy 36%
  • Survival 34%
  • Dacarbazine 26%

• IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

  Budde, E. L., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Wei, M. C., Yin, S., Doral, M. Y., Li, C. C., Huang, H., Negricea, R., Penuel, E., O'Hear, C., & 1 othersBartlett, N. L., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S387

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • Hypophosphatemia 27%
  • Alkylating Agents 23%
  • Neutropenia 20%
  • Hospitalization 15%

• Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

  Harkins, R. A., Patel, S. P., Lee, M. J., Switchenko, J. M., Ansell, S. M., Bartlett, N. L., Blum, K. A., Cashen, A. F., Casulo, C., Friedberg, J. W., Johnston, P. B., Kahl, B. S., Leonard, J. P., Link, B. K., Lossos, I. S., Martin, P., Maurer, M. J., Mehta-Shah, N., Reagan, P. M., Westin, J. R., & 2 othersKoff, J. L. & Flowers, C. R., May 10 2022, In: Blood Advances. 6, 9, p. 2745-2756 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Randomized Controlled Trials 59%
  • Lymphoma 18%
  • Rituximab 12%
  • Vincristine 12%

• Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

  Jaswal, S., Sanders, V., Pullarkat, P., Teja, S., Albright, A., Watkins, M. P., Atagu, N., Ludwig, D. R., Mhlanga, J., Mellnick, V. M., Peterson, L. R., Bartlett, N. L., Kahl, B. S., Fehniger, T. A., Ghobadi, A., Cashen, A. F., Mehta-Shah, N. & Ippolito, J. E., Jun 1 2022, In: Cancers. 14, 12, 2932.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Intra-Abdominal Fat 99%
  • Biomarkers 57%
  • Neoplasms 16%
  • Positron Emission Tomography Computed Tomography 13%

• Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

  Hamid, M. S., Rutherford, S. C., Jang, H., Kim, S., Patel, K., Bartlett, N. L., Malecek, M. K., Watkins, M. P., Maddocks, K. J., Bond, D. A., Feldman, T. A., Magarelli, G., Advani, R. H., Spinner, M. A., Evens, A. M., Shah, M., Ahmed, S., Stephens, D. M., Allen, P., Tees, M. T., & 7 othersKarmali, R., Cheson, B. D., Yazdy, M. S., Strouse, C., Bailey, N. A., Pagel, J. M. & Ramchandren, R., Jul 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 7, p. e435-e442

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Positron-Emission Tomography 90%
  • Progression-Free Survival 14%
  • Therapeutics 13%
  5 Scopus citations

• Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

  the ECHELON-1 Study Group, Jul 28 2022, In: New England Journal of Medicine. 387, 4, p. 310-320 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Hodgkin Disease 64%
  • Survival 34%
  • Progression-Free Survival 18%
  • Dacarbazine 17%
  63 Scopus citations

• Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

  Halwani, A. S., Panizo, C., Isufi, I., Herrera, A. F., Okada, C. Y., Cull, E. H., Kis, B., Chaves, J. M., Bartlett, N. L., Ai, W., de la Cruz-Merino, L., Bryan, L. J., Houot, R., Linton, K., Briones, J., Chau, I., von Keudell, G. R., Lu, H., Yakovich, A., Chen, M., & 4 othersMeulen JH, T., Yurasov, S., Hsu, F. J. & Flowers, C. R., 2022, In: Leukemia and Lymphoma. 63, 4, p. 821-833 13 p.

  Research output: Contribution to journal › Article › peer-review

  • pembrolizumab 100%
  • Follicular Lymphoma 87%
  • Toll-Like Receptor 4 81%
  • Neoplasms 22%
  • Injections 20%
  5 Scopus citations

• Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

  Ward, J. P., Berrien-Elliott, M. M., Gomez, F., Luo, J., Becker-Hapak, M., Cashen, A. F., Wagner-Johnston, N. D., Maddocks, K., Mosior, M., Foster, M., Krysiak, K., Schmidt, A., Skidmore, Z. L., Desai, S., Watkins, M. P., Fischer, A., Griffith, M., Griffith, O. L., Fehniger, T. A. & Bartlett, N. L., Mar 31 2022, In: Blood. 139, 13, p. 1999-2010 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Lenalidomide 100%
  • Brentuximab Vedotin 88%
  • Lymphoma, Large B-Cell, Diffuse 62%
  • Refractory 57%
  • Dose 42%
  8 Scopus citations

• Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

  Martin, P., Bartlett, N. L., Chavez, J. C., Reagan, J. L., Smith, S. M., LaCasce, A. S., Jones, J., Drew, J., Wu, C., Mulvey, E., Revuelta, M. V., Cerchietti, L. & Leonard, J. P., Feb 24 2022, In: Blood. 139, 8, p. 1147-1159 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Maximum Tolerated Dose 100%
  • Azacitidine 77%
  • Lymphoma, Large B-Cell, Diffuse 65%
  • Safety 49%
  • Prednisone 45%
  16 Scopus citations

• Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

  Epperla, N., Zhao, Q., Chowdhury, S. M., Shea, L., Moyo, T. K., Reddy, N., Sheets, J., Weiner, D. M., Geethakumari, P. R., Kandarpa, M., Bruno, X. J., Thomas, C., Churnetski, M. C., Hsu, A., Zurbriggen, L., Tan, C., Lindsey, K., Maakaron, J., Caimi, P. F., Torka, P., & 25 othersBello, C., Ayyappan, S., Karmali, R., Kim, S. H., Kress, A., Kothari, S., Sawalha, Y., Christian, B., David, K. A., Greenwell, I. B., Janakiram, M., Kenkre, V. P., Olszewski, A. J., Cohen, J. B., Palmisiano, N., Umyarova, E., Wilcox, R. A., Awan, F. T., Alderuccio, J. P., Barta, S. K., Grover, N. S., Ghosh, N., Bartlett, N. L., Herrera, A. F. & Shouse, G., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 96.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • PCI 32765 100%
  • Multicenter Studies 58%
  • Lymphoma 55%
  • Cohort Studies 45%
  • Cytogenetics 13%
  2 Scopus citations

• Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

  Jagadeesh, D., Horwitz, S., Bartlett, N. L., Kim, Y., Jacobsen, E., Duvic, M., Little, M., Trepicchio, W., Fenton, K., Onsum, M., Lisano, J. & Advani, R., Oct 2022, In: Oncologist. 27, 10, p. 864-873 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Non-Hodgkin's Lymphoma 59%
  • Peripheral T-Cell Lymphoma 28%
  • Cutaneous T-Cell Lymphoma 27%
  • Immunohistochemistry 21%
  5 Scopus citations

• Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

  Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C. C., Huang, H., Kwan, A., Penuel, E. & Bartlett, N. L., Aug 2022, In: The Lancet Oncology. 23, 8, p. 1055-1065 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Bispecific Antibodies 100%
  • Follicular Lymphoma 87%
  • Safety 41%
  • 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide 19%
  • Advisory Committees 10%
  73 Scopus citations

• Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

  Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S. S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C. C., Piccione, E. C., Wei, M. C., Yin, S., & 1 othersBartlett, N. L., Feb 10 2022, In: Journal of Clinical Oncology. 40, 5, p. 481-491 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Non-Hodgkin's Lymphoma 75%
  • Cytokine Release Syndrome 51%
  • Bispecific Antibodies 22%
  • Hypophosphatemia 21%
  114 Scopus citations

• Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R²) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

  Morschhauser, F., Nastoupil, L., Feugier, P., De Colella, J. M. S., Tilly, H., Palomba, M. L., Bachy, E., Fruchart, C., Libby, E. N., Casasnovas, R. O., Flinn, I. W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N. L., Bouabdallah, K., Brice, P., Ribrag, V., Le Gouill, S., Daguindau, N., & 17 othersGuidez, S., Pica, G. M., García-Sancho, A. M., López-Guillermo, A., Larouche, J. F., Ando, K., Gomes Da Silva, M., André, M., Kalung, W., Sehn, L. H., Izutsu, K., Cartron, G., Gkasiamis, A., Crowe, R., Xerri, L., Fowler, N. H. & Salles, G., Oct 1 2022, In: Journal of Clinical Oncology. 40, 28, p. 3239-3245 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Follicular Lymphoma 92%
  • Rituximab 81%
  • Maintenance 52%
  • Drug Therapy 44%
  8 Scopus citations

• Stem cell transplant for lymphoma - never too late?

  Cashen, A. F. & Bartlett, N. L., May 2022, In: Haematologica. 107, 5, p. 1024-1025 2 p.

  Research output: Contribution to journal › Editorial

  Open Access

• The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

  Horwitz, S., O'Connor, O. A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illés, Tobinai, K., Tsukasaki, K., Yeh, S. P., Shustov, A., & 10 othersHüttmann, A., Savage, K. J., Yuen, S., Zinzani, P. L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M. & Illidge, T., Mar 2022, In: Annals of Oncology. 33, 3, p. 288-298 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Peripheral T-Cell Lymphoma 85%
  • Progression-Free Survival 40%
  • Drug Therapy 36%
  • Confidence Intervals 32%
  70 Scopus citations
• 2021

  Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

  Ruppert, A. S., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Coutre, S., Brown, J. R., Nattam, S., Larson, R. A., Erba, H., Litzow, M., Owen, C., Kuzma, C. S., Abramson, J. S., Little, R. F., Smith, S. E., Stone, R. M., Byrd, J. C., Mandrekar, S. J. & Woyach, J. A., Oct 2021, In: Leukemia. 35, 10, p. 2854-2861 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Bendamustine Hydrochloride 100%
  • PCI 32765 96%
  • Rituximab 70%
  • Incidence 7%
  • Duration of Therapy 7%
  10 Scopus citations

• A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma

  Russler-Germain, D. A., Watkins, M. P. & Bartlett, N. L., 2021, In: Leukemia and Lymphoma. 62, 2, p. 486-488 3 p.

  Research output: Contribution to journal › Letter › peer-review

• Author Correction: Hodgkin lymphoma (Nature Reviews Disease Primers, (2020), 6, 1, (61), 10.1038/s41572-020-0189-6)

  Connors, J. M., Cozen, W., Steidl, C., Carbone, A., Hoppe, R. T., Flechtner, H. H. & Bartlett, N. L., Dec 2021, In: Nature Reviews Disease Primers. 7, 1, 79.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Cellular Microenvironment 100%
  • Hodgkin Disease 81%
  1 Scopus citations

• B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

  Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., de Vos, S., Dholaria, B., Fakhri, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Hernandez-Ilizaliturri, F., Hsi, E., Hu, B., Kaminski, M. S., Kelsey, C. R., & 17 othersKhan, N., Krivacic, S., LaCasce, A. S., Lim, M., Narkhede, M., Rabinovitch, R., Ramakrishnan, P., Reid, E., Roberts, K. B., Saeed, H., Smith, S. D., Svoboda, J., Swinnen, L. J., Tuscano, J., Vose, J. M., Dwyer, M. A. & Sundar, H., Nov 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 11, p. 1218-1230 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Guidelines 62%
  • Adoptive Immunotherapy 31%
  • Mantle-Cell Lymphoma 31%
  • Follicular Lymphoma 29%
  63 Scopus citations

• Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy

  Sohani, A. R., Maurer, M. J., Giri, S., Pitcher, B., Chadburn, A., Said, J. W., Bartlett, N. L., Czuczman, M. S., Martin, P., Rosenbaum, C. A., Jung, S. H., Leonard, J. P., Cheson, B. D. & Hsi, E. D., Mar 2021, In: American Journal of Surgical Pathology. 45, 3, p. 384-393 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • Biological Therapy 96%
  • Progression-Free Survival 73%
  • Biomarkers 52%
  • Lenalidomide 18%
  8 Scopus citations

• Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

  Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Christian, B. A., Ansell, S. M., Moskowitz, C. H., Brown, L., Zhang, C., Taft, D., Ansari, S., Sacchi, M., Ho, L. & Herrera, A. F., Aug 12 2021, In: Blood. 138, 6, p. 427-438 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Nivolumab 85%
  • Adrenal Cortex Hormone 80%
  • Refractory 64%
  • Hodgkin Disease 64%
  83 Scopus citations

• Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

  Straus, D. J., Długosz-Danecka, M., Connors, J. M., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Munoz, J., Lee, H. J., Kim, W. S., Advani, R., Ansell, S. M., & 7 othersYounes, A., Gallamini, A., Liu, R., Little, M., Fenton, K., Fanale, M. & Radford, J., Jun 2021, In: The Lancet Haematology. 8, 6, p. e410-e421

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Hodgkin Disease 64%
  • Progression-Free Survival 39%
  • Drug Therapy 36%
  • Dacarbazine 31%
  70 Scopus citations

• CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder

  Krishnamoorthy, S., Ghobadi, A., Santos, R. D., Schilling, J. D., Malone, A. F., Murad, H., Bartlett, N. L. & Alhamad, T., Feb 2021, In: American Journal of Transplantation. 21, 2, p. 809-814 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Lymphoproliferative Disorders 87%
  • Cell- and Tissue-Based Therapy 70%
  • Transplant Recipients 68%
  • Transplants 46%
  41 Scopus citations

• CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma

  Ghobadi, A. & Bartlett, N. L., Sep 25 2021, In: The Lancet. 398, 10306, p. 1109-1110 2 p.

  Research output: Contribution to journal › Comment/debate
  2 Scopus citations